Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.

Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. · 2016

Read Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. by Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5062546.txt.

Introduction

Samuel A. J. Trammell and nine co-authors test a vitamin in Nature Communications in 2016. Nicotinamide riboside is a precursor the body uses to build NAD+, a central helper molecule in energy metabolism, and it is sold widely as a supplement. Yet no study had measured how oral doses move NAD+ levels in people. The team gave single doses to mice and ran the first human pharmacokinetic trial of the compound.

In mice, the vitamin raised liver NAD+ better than its two rival precursors, nicotinic acid and nicotinamide. In one pilot volunteer, a single dose lifted blood NAD+ up to 2.7-fold. In the trial, doses of 100, 300, and 1,000 milligrams raised the blood NAD+ metabolite mix in step with dose. A byproduct called NAAD, not previously thought to sit on the path, rose sharply and proved the most sensitive sign that NAD+ stores had been refilled.

Catalog record

CREATORTrammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5062546

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans By Samuel A. J. Trammell, Mark S. Schmidt, Benjamin J. Weidemann, Philip Redpath, Frank Jaksch, Ryan W. Dellinger, Zhonggang Li, E. Dale Abel, Marie E. Migaud, Charles Brenner Published in: Nature Communications DOI: 10.1038/ncomms12948 ABSTRACT Nicotinamide riboside (NR) is in wide use as an NAD+ precursor vitamin. Here we determine the time and dose-dependent effects of NR on blood NAD+ metabolism in humans. We report that human blood NAD+ can rise as much as 2.7-fold with a single oral dose of NR in a pilot study of one individual, and that oral NR elevates mouse hepatic NAD+ with distinct and superior pharmacokinetics to those of nicotinic acid and nicotinamide. We further show that single doses of 100, 300 and 1,000 mg of NR produce dose-dependent increases in the blood NAD+ metabolome in the first clinical trial of NR pharmacokinetics in humans. We also report that nicotinic acid adenine dinucleotide (NAAD), which was not thought to be en route for the conversion of NR to NAD+, is formed from NR and discover that the rise in NAAD is a highly sensitive biomarker of effective NAD+ repletion. Nicotinamide adenine dinucleotide (NAD+), the central redox coenzyme in cellular metabolism12 functions as a hydride group acceptor, forming NADH with concomitant oxidation of metabolites derived from carbohydrates, amino acids and fats. The NAD+/NADH ratio controls the degree to which such reactions proceed in oxidative versus reductive directions. Whereas fuel oxidation reactions require NAD+ as a hydride acceptor, gluconeogenesis, oxidative phosphorylation, ketogenesis, detoxification of reactive oxygen species (ROS) and lipogenesis require reduced co-factors, NADH and NADPH, as hydride donors (Fig. 1). In addition to its role as a coenzyme, NAD+ is the consumed substrate of enzymes such as poly-ADPribose polymerases (PARPs), sirtuins and cyclic ADPribose synthetases1. In redox reactions, the biosynthetic structures of NAD+, NADH, NADP+ and NADPH are preserved. In contrast, PARP3, sirtuin4 and cyclic ADPribose synthetase5 activities hydrolyze the linkage between the nicotinamide (Nam) and the ADPribosyl moieties of NAD+ to signal DNA damage, alter gene expression, control post-translational modifications and regulate calcium signalling. In animals, NAD+-consuming activities and cell division necessitate ongoing NAD+ synthesis, either through a de novo pathway that originates with tryptophan or via salvage pathways from three NAD+ precursor vitamins, Nam, nicotinic acid (NA) and nicotinamide riboside (NR)2. Dietary NAD+ precursors, which include tryptophan and the three vitamins, prevent pellagra. Though NR is present in milk67, the cellular concentrations of NAD+, NADH, NADP+ and NADPH are much higher than those of other NAD+ metabolites89, such that dietary NAD+ precursor vitamins are largely derived from enzymatic breakdown of NAD+. Thus, although milk is a source of NR67, the more abundant sources of NR, Nam and NA are unprocessed foods, in which plant and animal cellular NAD+ metabolites are broken down to these compounds. Human digestion and the microbiome10 play roles in the provision of these vitamins in ways that are not fully characterized. In addition, the conventional NAD+ precursor vitamins, NA and Nam, have long been supplemented into human and animal diets to prevent pellagra and promote growth1112. Though NR has been available as a GMP-produced supplement since 2013 and animal safety assessment indicates that it is as nontoxic as Nam13, no human testing has been reported. Different tissues maintain NAD+ levels through reliance on different biosynthetic routes and precursors1415 (Fig. 1). Because NAD+-consuming activities frequently occur as a function of cellular stresses3 and produce Nam, the ability of a cell to salvage Nam into productive NAD+ synthesis through Nam phosphoribosyltransferase (NAMPT) activity versus methylation of Nam to N-methylnicotinamide (MeNam) regulates the efficiency of NAD+-dependent processes16. NAD+ biosynthetic genes are also under circadian control1718. Both NAMPT expression and NAD+ levels decline in a number of tissues as a function of aging and overnutrition19202122. High-dose NA but not high-dose Nam is prescribed to treat and prevent dyslipidemias, although its use is limited by painful flushing2324. Whereas it takes only ∼15 mg per day of NA or Nam to prevent pellagra, pharmacological doses of NA can be as high as 2–4 g. Despite the >100-fold difference in effective dose between pellagra prevention and dyslipidemia treatment, we proposed that the beneficial effects of NA on plasma lipids might simply depend on function of NA as an NAD+ boosting compound1. According to this view, sirtuin activation would likely be part of the mechanism because Nam is an NAD+ precursor in most cells1415 but inhibits sirtuins at high doses25. On the basis of the ability of NR to elevate NAD+ synthesis, increase sirtuin activity and extend lifespan in yeast626, NR has been employed in mice to elevate NAD+ metabolism and improve health in models of metabolic stress. Notably, NR allows mice to resist weight gain on high-fat diet27, prevent noise-induced hearing loss28 and maintain the regenerative potential of stem cells in aging mice, providing a longevity advantage29. In addition, the hepatic NAD+ metabolome has been interrogated as a function of prediabetic and type 2 diabetic mouse models. The data indicate that levels of liver NADP+ and NADPH, which are required for resistance to ROS, are severely challenged by diet-induced obesity, and that diabetes and the NAD+ metabolome can be partially controlled while diabetic neuropathy can be blocked by oral NR30. Data indicate that NR is a mitochondrially favoured NAD+ precursor31 and in vivo activities of NR have been interpreted as depending on mitochondrial sirtuin activities2728, though not to the exclusion of nucleocytosolic targets3233. Similarly, nicotinamide mononucleotide (NMN), the phosphorylated form of NR, has been used to treat declining NAD+ in mouse models of overnutrition and aging1920. Beneficial effects of NMN have been shown to depend on SIRT120. However, because of the abundance of NAD+-dependent processes, the effects of NR and NMN may depend on multiple targets including sirtuins, PARP family members, cADPribose synthetases, NAD+-dependent oxidoreductases and NADPH-dependent ROS detoxification enzymes30. To translate NR technologies to people, it is necessary to determine NR oral availability and utilization in different tissues. Here we began with targeted quantitative NAD+ metabolomics of blood and urine in a pilot experiment in which a healthy 52-year-old man took 1,000 mg of NR daily for 7 days. These data indicate that blood cellular NAD+ rose 2.7-fold after one dose of NR and that NA adenine dinucleotide (NAAD) unexpectedly increased 45-fold. We then performed a detailed analysis of 128 mice comparing oral NR, Nam and NA in a manner that eliminated the possibility of circadian artefacts. These data indicate that NR boosts hepatic NAD+ and NAD+- consuming activities to a greater degree than Nam or NA. Further experiments clarified that NR is a direct precursor of NAAD and that NAAD sensitively reports on increased NAD+ metabolism in mouse liver and heart. Finally, we performed a clinical study with 12 healthy human subjects at three single doses of NR. We demonstrated that NR supplementation safely increases NAD+ metabolism at all doses and validated elevated NAAD as an unexpected, sensitive biomarker of boosting NAD+. The unique oral bioavailability of NR in mice and people and methods established herein enable clinical translation of NR to improve wellness and treat human diseases. RESULTS Oral NR increases human blood NAD+ with elevation of NAAD GMP-synthesized NR showed no

Read the complete text